secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0001558370-23-011031
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor
--------------------------------------------------------------------------------

- Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.
- Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.
- Broker non-votes of 3,812,216 recorded on each director election.
- Annual meeting held June 8, 2023; all proposals passed with strong support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/xlo-20230608x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer